Procept BioRobotics EVP and CFO sells over $2 million in stock

Kevin Waters (NYSE:WAT ), the Executive Vice President and Chief Financial Officer of PROCEPT BioRobotics Corp (NASDAQ:PRCT), a company specializing in surgical and medical instruments, has recently sold a significant amount of company stock. According to the latest SEC filings, Waters sold shares with a total value exceeding $2 million.


The transactions, which took place on September 16, 2024, involved multiple sales of PROCEPT BioRobotics' common stock at varying prices. The weighted average selling prices for these sales ranged from $81.96 to $83.35 per share, with the total value of the sold shares amounting to approximately $2,062,679. The sales were conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information.


In addition to the sales, Waters also acquired shares through the exercise of stock options. The options, with exercise prices between $4.52 and $4.56, resulted in a total transaction value of $113,363. These stock options were part of a compensation plan that vested over a four-year period, with grant dates in October 2018 and December 2019.


Following these transactions, Waters' ownership in the company has seen changes, but the exact post-transaction share count remains part of the executive's portfolio details. Investors often monitor insider buying and selling as it can provide insights into an executive's confidence in the company's future performance.


PROCEPT BioRobotics Corp, headquartered in San Jose, California, continues to be at the forefront of developing innovative robotic technologies aimed at improving patient outcomes in urology procedures. The company's stock performance and insider transactions are closely watched by investors interested in the medical technology sector.



In other recent news, Procept BioRobotics Corp has been making significant strides, with analysts from TD Cowen, Truist Securities, and BofA Securities maintaining a Buy rating on the company's stock. The FDA recently granted clearance to the company's Hydros Robotic System, a development that has been met with increased price targets from these firms, reflecting confidence in the company's growth trajectory. The Hydros system, equipped with AI-driven treatment planning and advanced image guidance, is expected to improve clinical procedures' efficiency and outcomes.


Procept BioRobotics has also reported a substantial 61% increase in total earnings for its second quarter of 2024, reaching $53.4 million, despite a reported net loss of $25.6 million. This financial growth is attributed to strong U.S. system sales, an expanded U.S. install base, and record international revenues. These recent developments highlight the company's robust financial growth and product advancements.


In addition to the excitement around Hydros, Procept BioRobotics has been advancing in the prostate cancer space, with the completion of the 002 trial enrollment marking a significant milestone in the company's efforts. The Hydros system and its prostate cancer treatments are anticipated to be key contributors to the company's future success. The raised price targets signify the firms' belief in the company's potential and the promising developments in its product pipeline.
InvestingPro Insights


In light of the recent insider transactions at PROCEPT BioRobotics Corp (NASDAQ:PRCT), investors may find it valuable to consider the company's financial health and market performance as part of their analysis. Here are some insights based on real-time data and InvestingPro Tips:


PROCEPT BioRobotics has shown a notable revenue growth with a 73.74% increase over the last twelve months as of Q2 2024, indicating a strong expansion in its financial operations. Despite the company's growth, analysts have expressed concerns about its profitability, suggesting that PROCEPT may not achieve profitability this year. This aligns with the company's current P/E Ratio of -27.89, which reflects investor sentiment about the company's future earnings potential.


On the market performance front, PROCEPT has experienced a significant price uptick over the last six months, with a 70.37% total return, and is currently trading near its 52-week high, at 96.69% of the peak price. This could indicate strong investor confidence or speculative interest in the stock. However, it's important to note that the company is trading at a high Price / Book multiple of 17.11, which could suggest that the stock is valued richly compared to its book value.


InvestingPro Tips highlight that while PROCEPT has a high return over the last year, with a 151.04% total return, the company operates with a moderate level of debt and its liquid assets exceed short term obligations, providing some financial stability. Yet, it's trading at a high revenue valuation multiple, which could be a point of caution for value-focused investors.


For those looking to delve deeper into PROCEPT BioRobotics' financials and market performance, InvestingPro offers additional tips and metrics. Currently, there are 12 more InvestingPro Tips available for PROCEPT BioRobotics at https://www.investing.com/pro/PRCT, which could further inform investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com